DMRA

SEC source: 0000947871-23-000472 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 182,504

F1 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 9

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,464,234

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 8

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 985,647

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel") is the general partner of OIP II and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 7

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 183,207

F1 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 6

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,465,837

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 986,288

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel") is the general partner of OIP II and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 183,326

F1 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,500,582

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,000,187

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel") is the general partner of OIP II and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000452 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 185,910

F1 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000438 · ownership.xml · nonDerivative · entry 6

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,510,041

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000438 · ownership.xml · nonDerivative · entry 5

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,003,971

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel") is the general partner of OIP II and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000438 · ownership.xml · nonDerivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 186,613

F1 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000438 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,516,599

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000438 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,006,591

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel") is the general partner of OIP II and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the general partner of OrbiMed Israel. By virtue of such relationships, OrbiMed Limited and OrbiMed Israel may be deemed to have voting power and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises voting and investment power through a management committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000438 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · 10% owner

OrbiMed Capital GP VII LLC · CIK 0001760648 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 187,100

F1 · ownership.nature: These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis.

F4 · ownership.nature: Each of OrbiMed Advisors, Genesis GP, OrbiMed Israel, OrbiMed Limited, and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-23-001758 · doc4.xml · derivative · entry 1

Winslow Garrett · CIK 0001803773 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-23-001756 · doc4.xml · derivative · entry 1

Freve Jonathan · CIK 0001664466 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-23-001760 · doc4.xml · derivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-23-001757 · doc4.xml · derivative · entry 1

Oestreich Stephanie · CIK 0001901450 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-23-001755 · doc4.xml · derivative · entry 1

Lindmark Bertil · CIK 0001825778 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-23-001759 · doc4.xml · derivative · entry 1

Pedersen Anders · CIK 0001825779 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-22-036932 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2032-06-13

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

SEC source: 0001209191-22-036935 · doc4.xml · derivative · entry 1

Shapiro David · CIK 0001559570 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-06-13

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

SEC source: 0001209191-22-036933 · doc4.xml · derivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-06-13

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

SEC source: 0001209191-22-036936 · doc4.xml · derivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-06-13

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

SEC source: 0001209191-22-036931 · doc4.xml · derivative · entry 1

Dallas Jayson Donald Alexander · CIK 0001650322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-06-13

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

SEC source: 0001209191-22-036934 · doc4.xml · derivative · entry 1

Prener Anne · CIK 0001797917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-06-13

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

SEC source: 0001209191-22-020683 · doc4.xml · nonDerivative · entry 1

Lindmark Bertil · CIK 0001825778 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,604

SEC source: 0001209191-22-020682 · doc4.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,428

SEC source: 0001209191-22-009735 · doc4.xml · derivative · entry 1

Oestreich Stephanie · CIK 0001901450 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2032-02-14

F1 · derivative.exercise_date: 25% of the shares subject to such option will vest and become exercisable on January 5, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-22-002213 · doc4.xml · derivative · entry 1

Winslow Garrett · CIK 0001803773 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-22-002211 · doc4.xml · derivative · entry 1

Freve Jonathan · CIK 0001664466 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,750

Underlying: Common Stock · 118,750 shares

Expires 2032-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-22-002215 · doc4.xml · derivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,500

Underlying: Common Stock · 287,500 shares

Expires 2032-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-22-002214 · doc4.xml · derivative · entry 1

Lindmark Bertil · CIK 0001825778 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,750

Underlying: Common Stock · 118,750 shares

Expires 2032-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-22-002212 · doc4.xml · derivative · entry 1

Pedersen Anders · CIK 0001825779 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,750

Underlying: Common Stock · 118,750 shares

Expires 2032-01-03

F1 · derivative.exercise_date: 25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-21-068028 · doc4.xml · nonDerivative · entry 1

Winslow Garrett · CIK 0001803773 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

SEC source: 0001209191-21-068027 · doc4.xml · nonDerivative · entry 1

Freve Jonathan · CIK 0001664466 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

SEC source: 0001209191-21-065841 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-11-16

F1 · security: This stock option was granted to the Reporting Person for serving as the Chair of the Board.

F2 · derivative.exercise_date: Shares subject to the option vest in equal monthly installments beginning July 1, 2021, when the Reporting Person became the Chair of the Board of the Issuer, until July 1, 2022.

SEC source: 0001209191-21-065847 · doc4.xml · derivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2031-11-16

F1 · security: This stock option was awarded to the Reporting Person in recognition for his work as a board member with respect to the strategic efforts of the Company.

F2 · derivative.exercise_date: Shares subject to the option vest in equal monthly installments until the first anniversary of the grant date.

SEC source: 0001209191-21-063798 · doc4.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,428

SEC source: 0001209191-21-063523 · doc4.xml · nonDerivative · entry 1

Freve Jonathan · CIK 0001664466 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

SEC source: 0001209191-21-052512 · doc4.xml · nonDerivative · entry 1

Freve Jonathan · CIK 0001664466 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001209191-21-043464 · doc4.xml · nonDerivative · entry 1

Lindmark Bertil · CIK 0001825778 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

SEC source: 0001209191-21-042986 · doc4.xml · nonDerivative · entry 1

Schambye Hans T. · CIK 0001825776 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,928

SEC source: 0001209191-21-042718 · doc4.xml · nonDerivative · entry 1

Winslow Garrett · CIK 0001803773 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

SEC source: 0001209191-21-042719 · doc4.xml · nonDerivative · entry 1

Freve Jonathan · CIK 0001664466 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

SEC source: 0001209191-21-040944 · doc4.xml · derivative · entry 1

Winslow Garrett · CIK 0001803773 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2031-06-14

F1 · derivative.exercise_date: 25% of the shares subject to such option will vest and become exercisable on May 2, 2022 and the remainder of the shares will vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-21-036507 · doc4.xml · derivative · entry 1

GOLDFISCHER CARL · CIK 0001110780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-05-25

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

SEC source: 0001209191-21-036509 · doc4.xml · derivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-05-25

F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, OrbiMed Advisors Israel II Limited, and OrbiMed Israel GP II, L.P., the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, OrbiMed Advisors Israel II Limited, and OrbiMed Israel GP II, L.P., which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, L.P. and OrbiMed Israel Partners II, L.P.